Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
doi 10.1002/14651858.cd011346.pub2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Scientific Reports
Multidisciplinary
2019English

Aflibercept Improves Outcome in Eyes With Poor Vision From Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2016English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

One Year Effectiveness Study of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Acta Ophthalmologica
MedicineOphthalmology
2018English

Retinal Metabolic and Structural Alterations in Response to Aflibercept Treatment in Neovascular Age‐related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2018English

Change in Choroidal Thickness After Intravitreal Aflibercept in Pretreated and Treatment-Naive Eyes for Neovascular Age-Related Macular Degeneration

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2015English

Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data From an Observational Study

Ophthalmology
Ophthalmology
2016English

Cost-Effectiveness of Intravitreal Aflibercept Injection (IAI) in Treating Neovascular Age-Related Macular Degeneration in the US

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy